Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus -Long-term Study of Rosiglitazone Maleate-

NCT00523913 Phase 3 COMPLETED

This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 3
Status	COMPLETED
Enrolment	70
Start date	2005-11
Completion	2007-04

Conditions

• Diabetes Mellitus, Type 2

Interventions

• rosiglitazone

Primary outcomes

• The safety profile (adverse events, laboratory parameters and other observations) of BRL49653C administered for 52 weeks will be evaluated. — 52 Weeks